Strand Life Sciences Private Limited

San Francisco,  CO 
United States
http://www.strandls.com
  • Booth: 1017

Strand Life Sciences, is a global genomic profiling and bioinformatics company. Strand is a leader in precision medicine diagnostics with CAP and NABL accredited NGS laboratory in India. Strand works with researchers, oncologists, pathologists, geneticists, and hospitals to enable faster clinical decision support including molecular diagnosis, prognosis, therapy recommendations, and clinical trials. Established in 2000, Strand has been a technology innovation company that has pioneered the practice of scientific intelligence in health sciences.

www.strandls.com

Brands: Strand NGS, GeneSpring, Strand iMANAGE, Bioinformatic data analysis service, Clinical Diagnostics Services, Data Mining Algorithms and Management Systems, Visualization Solutions, Knowledge Curation


 Press Releases

  • Strand Life Sciences will present eight posters at the 67th Annual Meeting of the American Society of Human Genetics (ASHG), held at Orlando, Florida from 17-21 October 2017. Each poster represents a case study utilizing Strand NGS’s extensive range of features for the various next-generation sequencing (NGS) applications, including the detection of novel small RNAs in single-cell experiments and identifying long-range epigenetic activation domains in multi-omics datasets. All studies were conducted in Strand NGS, a software for secondary and tertiary NGS analysis from Strand Life Sciences.

    Below is a brief summary of each of the case studies:

    1. Somatic best-practices for Strand NGS DNA-Seq.
      Showcases the fast and accurate somatic DNA-Seq workflow in Strand NGS.

    2. Detection of novel small RNAs in Strand NGS.
      Showcases the detection of novel small RNAs in a single-cell study in Strand NGS.

    3. Identifying LREA regions in prostate cancer cell lines.
      Integrates DNA, chromatin, and DNA methylation genome-wide profiles in Strand NGS, identifying 35 long-range epigenetic activation (LREA) domains across 251 genes.

    4. Postoperative risk prediction for patients with advanced heart failure (study conducted jointly with Mario Deng, UCLA).
      Integrates transcriptome, flow cytometry, and cytokine data to build a class prediction model in Strand NGS, predicting postoperative risk prediction in patients with heart failure.

    5. Drug resistance in basal cell carcinoma.
      Integrates genomic, transcriptomic, and proteomic data in Strand NGS to explain drug resistance in basal cell carcinomas.

    6. Regulation of cardiogenesis.
      Integrated Analysis of RNA-Seq and ChIP-Seq data in Strand NGS to find binding domains implicated in infant cardiogenesis as well as their impact on gene expression.

    7. Predicting functional recovery in heart failure patients (study conducted jointly with Galyna Bondar, UCLA).
      Integrates age and transcriptome markers in Strand NGS to predict functional recovery in patients with heart failure.

    8. Large-scale study of over 1000 Indian patients with HBOC.
      Showcases the fast and accurate variant calling feature of Strand NGS including detection of large deletions and insertions from single exons to full genes.

        

    These studies, conducted by application scientists, developers, and biologists at Strand Life Sciences, highlight two major themes currently dominating the life sciences. The first is integration. Five of the eight studies represent multi-omic-analyses spanning several data types, displaying the intuitive interface and deep interrogation methods that Strand NGS provides. The second theme is diversity: the studies span DNA, RNA, small-RNA, Methyl and MeDIP-Seq workflows, showcasing the breadth of workflows available in Strand NGS as well as the way they interact seamlessly with each other allowing scientists to work and collaborate across domains. For more details, access the detailed agenda on our posters here.

    At ASHG, Strand Life Sciences will also announce the release of the latest version of Strand NGS, v3.1. This will contain exciting new features supporting large-scale RNA-Seq analysis, Unique Molecular Identifiers (UMIs) and many new and intuitive visualizations. Visit our booth #1017 at ASHG to find out more about this latest version of Strand NGS. For more information on Strand NGS, visit www.strand-ngs.com

    About Strand

    Strand Life Sciences is a premier life science informatics innovation company. Founded in 2000, Strand is a leader in technology innovations for healthcare using genomics. By enhancing sequence-based diagnostics and clinical genomic data interpretation using a strong foundation of computational, scientific, and medical expertise, Strand is bringing individualized medicine to the world. To know more, visit www.strandls.com  

  • ORLANDO, USA, Oct 17, 2017/ ASHG2017/

    Strand NGS now supports large scale RNA- and small-RNA-Seq and Unique Molecular Identifiers (UMIs) for DNA-, RNA-, and small-RNA-Seq.

     

    Strand Life Sciences announced the latest version release of its bioinformatics flagship product, Strand NGS, at the Annual Meeting of the American Society of Human Genetics today. Two major themes in Strand NGS v3.1 address recent challenges in next generation sequencing (NGS).

    The first theme is large-scale RNA-Seq data analysis. Current cross-cohort RNA- and small-RNA-Seq studies span tens of replicates and batches across hundreds of samples, sometimes conducted across several different institutions. For such studies, Strand NGS v3.1 includes confounding variable analysis to eliminate technical effects, including batch effects; the t-SNE plot; profile and heat-map plots of gene-body coverage; and several other notable visual enhancements.

    The second new feature is support for Unique Molecular Identifiers, or UMIs, for DNA-, RNA- and small-RNA-Seq. UMI support in Strand NGS is end-to-end, spanning alignment to variant calling in DNA-Seq, and alignment to quantification in RNA- and small-RNA-Seq. The Bioo Scientific, Qiagen, and Rubicon UMI protocols are natively supported, and an intuitive interface allows the specification of custom UMI protocols.

    “For liquid biopsies and low-grade FFPE samples, UMI support in DNA-Seq enables the detection of somatic variants at low concentrations. In RNA-Seq, large-scale and UMI support can be used in single-cell-based studies that reveal tumor-cell heterogeneity, even at low concentrations”, says Dr. Vamsi Veeramachaneni, Chief Scientific Officer, Strand Life Sciences.  

    “At Strand, we are continuously working towards improving the accuracy and efficiency of NGS data analysis. Customers can look forward to Strand NGS becoming available on the cloud in the near future”, says Dr. Ramesh Hariharan, Chief Executive Officer, Strand Life Sciences.

    Visit Strand Life Sciences at ASHG booth #1017 to know more about Strand NGS v3.1 and other products and service offerings from Strand Life Sciences. Click here to access detailed agenda and v3.1 release notes.

    About Strand Life Sciences

    Strand Life Sciences is a premier life science informatics innovation company. Founded in 2000, Strand is a leader in technology innovations for healthcare using genomics. By enhancing sequence-based diagnostics and clinical genomic data interpretation using a strong foundation of computational, scientific, and medical expertise, Strand is bringing individualized medicine to the world. To know more, visit www.strandls.com

  • Scientists from Strand Life Sciences will demonstrate ‘Strand NGS’, an all-in-one next generation sequencing software at the 67th Annual Meeting of the American Society of Human Genetics (ASHG) to be held from Oct 17 to 21 in Orlando, Florida.Strand is excited to be an exhibitor at ASHG 2017 and will use this opportunity to showcase the features of its flagship product, Strand NGS, which include: read alignment, analysis, data management, and its best-in-class visualization tools for next generation sequencing data.

    Latest version of Strand NGS (v3.0) had seen many improvements with respect to speed, accuracy, and performance of its DNA-Seq workflow when compared to the BWA-GATK best practices workflow. This version also included one-shot pipeline execution, improved RNA-Seq performance, TSS plots and full support for HGVS notations for SNP effect analysis.

    Strand NGS also added considerable value to Strand’s stack of artificial intelligence (AI)-powered bioinformatics and text mining platforms, called ‘Ramanujan’, aptly named after two great intellectuals of Indian origin (S. Ramanujan (1887-1920) and A.K. Ramanujan (1929-1993). Strand NGS along with the variant interpretation platform StrandOmics span next-generation genomics data analysis, clinical variant interpretation and reporting. With Ramanujan, Strand has enabled clinicians to integrate phenotype information with all other clinical reporting for more effective application in monitoring and screening of disease progression and recurrence.

    Strand NGS is developed on award winning platform ‘Avadis’ which is being used by researchers across the globe from academic institutes, clinical labs, and pharmaceutical companies. Strand NGS offers total licensing flexibility ranging from a single user desktop version to an enterprise version (Server Edition) that enables very efficient data analysis, data sharing, and collaboration across many teams. At ASHG 2017, Strand will also present eight posters in the sessions on ‘Cancer’, ‘Bioinformatics and Computational Approaches’ and ‘Cardiovascular Phenotypes’. These posters will highlight the strengths of the tool by using case studies performed at Strand. A schedule of these poster sessions is available on the Strand NGS website.

    About Strand NGS:

    Strand NGS (formerly Avadis NGS) is an integrated next-generation sequencing data analysis software that supports extensive workflows for read alignment, DNA-Seq, RNA-Seq, small RNA-Seq, Methyl-Seq, MeDIP-Seq, and ChIP-Seq experiments. Strand will showcase new features in Strand NGS such as the enhanced speed and accuracy of SNP calling, UMI support for DNA, RNA and small RNA-Seq data, one-shot pipelines, multi-omic analysis, and the best-in-class visualizations that the tool offers. To know more, visit www.strand-ngs.com

    About Strand

    Strand Life Sciences is a premier life science informatics innovation company. Founded in 2000, Strand is a leader in technology innovations for healthcare using genomics. By enhancing sequence-based diagnostics and clinical genomic data interpretation using a strong foundation of computational, scientific, and medical expertise, Strand is bringing individualized medicine to the world. To know more, visit www.strandls.com

Questions or Need Assistance?

Email exhibits@ashg.org

Technical support: Support

For more tips, visit the FAQ.

Featured Products
View All

Want your product featured here? Click to upgrade your online exhibitor listing.